Roberto Carmagnani Pestana1, Melody Becnel1, Maria Laura Rubin2, Danice K Torman3, James Crespo4, Jack Phan5, Ehab Hanna6, Diana Bell7, Bonnie S Glisson3, Jason M Johnson8, J Jack Lee2, Renata Ferrarotto9. 1. Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, United States. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, United States. 3. Department of Thoracic, Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, United States. 4. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, United States. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, United States. 6. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, United States. 7. Department of Pathology, The University of Texas MD Anderson Cancer Center, United States. 8. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, United States. 9. Department of Thoracic, Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, United States. Electronic address: rferrarotto@mdanderson.org.
Abstract
OBJECTIVES: Prior reports have demonstrated a potential enhancement in overall response rate (ORR) to chemotherapy after exposure to immunotherapy. The goal of this study was to evaluate the ORR and survival to chemotherapy and/or targeted therapy in head and neck squamous cell carcinoma (HNSCC) patients who progressed on immune checkpoint inhibitors (ICI). MATERIALS AND METHODS: We retrospectively collected clinical and pathologic data from patients with recurrent/metastatic HNSCC who progressed on ICI and subsequently received chemotherapy or targeted therapy. ORR was assessed by RECIST version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. RESULTS: A total of 43 patients met criteria for inclusion. The majority were male (91%) and former smokers (60%). Most patients received ICI as first-line (58.14%); the vast majority was platinum exposed (90.7%). The ORR to ICI was 21%. The ORR to systemic therapy before ICI was 47%, and the ORR after ICI failure was 42%. After progression on ICI, the median PFS and OS on the subsequent line of therapy were 4.2 and 8.4 months respectively. CONCLUSION: In our cohort of recurrent/metastatic HNSCC patients, the ORR and OS to systemic therapy after progression on ICI were higher than historical controls for second-line or beyond. Further investigations are warranted to better characterize optimal sequencing and combination strategies.
OBJECTIVES: Prior reports have demonstrated a potential enhancement in overall response rate (ORR) to chemotherapy after exposure to immunotherapy. The goal of this study was to evaluate the ORR and survival to chemotherapy and/or targeted therapy in head and neck squamous cell carcinoma (HNSCC) patients who progressed on immune checkpoint inhibitors (ICI). MATERIALS AND METHODS: We retrospectively collected clinical and pathologic data from patients with recurrent/metastatic HNSCC who progressed on ICI and subsequently received chemotherapy or targeted therapy. ORR was assessed by RECIST version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. RESULTS: A total of 43 patients met criteria for inclusion. The majority were male (91%) and former smokers (60%). Most patients received ICI as first-line (58.14%); the vast majority was platinum exposed (90.7%). The ORR to ICI was 21%. The ORR to systemic therapy before ICI was 47%, and the ORR after ICI failure was 42%. After progression on ICI, the median PFS and OS on the subsequent line of therapy were 4.2 and 8.4 months respectively. CONCLUSION: In our cohort of recurrent/metastatic HNSCC patients, the ORR and OS to systemic therapy after progression on ICI were higher than historical controls for second-line or beyond. Further investigations are warranted to better characterize optimal sequencing and combination strategies.
Authors: Marcell Costa de Medeiros; Min Liu; Rajat Banerjee; Emily Bellile; Nisha J D'Silva; Carlos Rossa Journal: Cell Oncol (Dordr) Date: 2022-03-10 Impact factor: 7.051